SpaceX IPO, Tariff Headwinds, and a Hefty Rebalancing: The MSCI World ETF’s June Gauntlet

URTH at record high faces headwinds from MSCI rebalancing, potential SpaceX mega-IPO, new pharma tariffs, and a divided Federal Reserve.

The iShares MSCI World ETF (URTH) is sitting on a fresh annual high of $202.67, but the path from here looks anything but smooth. A cluster of structural events — a major index overhaul, a blockbuster space-sector IPO, and a new round of pharmaceutical tariffs — threatens to test the fund’s resilience in the weeks ahead. Add an unusually divided Federal Reserve to the mix, and the next few trading sessions could define the ETF’s trajectory into summer.

A Rebalancing That Carries Weight

On May 29, MSCI will implement the changes from its latest index review, with the formal cut-off for the new composition set for June 1. The three largest additions are all US-listed names: Medline A, MasTec and TechnipFMC. Because the prior adjustment was deliberately modest, this round demands significantly higher trading volume — a meaningful event for a physically replicating fund like URTH, which must buy and sell actual securities.

The top-heavy nature of the index amplifies the effect. Nvidia, Apple and Microsoft alone account for nearly 14% of the portfolio. Nvidia remains the single largest holding at 6.36%, followed by Apple at 4.86% and Microsoft at 3.21%. All told, the ten largest positions represent about 27.5% of the fund, and the information technology sector commands roughly 29.9% of the weight.

The SpaceX Wild Card

Potentially the biggest external shock comes from outside the traditional blue-chip universe. SpaceX has confidentially filed for an IPO with the SEC, targeting a valuation between $1.75 trillion and $2 trillion. If the company qualifies for Nasdaq’s fast-entry rule, index-driven capital could flood in quickly. A subsequent MSCI inclusion would tilt the fund further toward technology and aerospace, reshaping its sector profile beyond what the scheduled additions already promise.

The stakes are high: the ETF already holds more than 1,000 stocks across 23 developed markets, covering about 85% of the free-float market capitalisation in each country. Any new mega-cap addition would add significant single-name risk to an already concentrated top slice.

Pharma Tariffs and Fed Hawks

Around a tenth of the URTH portfolio sits in healthcare, a sector now bracing for a direct US policy hit. Starting at the end of July, the US government will slap a 15% tariff on imported patent medicines from the EU, Japan, South Korea and Switzerland, and a 10% tariff on British pharmaceuticals. Analysts expect the levies to add roughly half a percentage point to inflation while squeezing margins across the industry. FactSet has already trimmed earnings forecasts for the sector.

The inflationary backdrop is already deteriorating. US consumer prices climbed to 3.8% in April, the highest reading since May 2023, driven largely by an 18% surge in energy costs tied to the Iran conflict. The Federal Reserve held its benchmark rate at 3.50% to 3.75% at its last meeting, but the vote was an unusually tight 8-4. Futures markets now price in roughly a one-in-three chance of a rate hike before year-end, and have fully written off any cuts for 2026. For an ETF whose technology weighting alone approaches 29%, a hawkish turn is no side issue.

Technical Fever, Firm Valuations

The fund’s short-term technical picture looks stretched. The relative strength index has climbed to 94.6, deep into overbought territory, while annualised volatility stands at 13.94%. A first support level lies around $200.32, with the most recent closing price of $199.92 sitting just 1.39% below the 52-week high of $202.74. On a fundamental basis, the ETF is not cheap: the price-to-earnings ratio stood at 25.75 in mid-May.

Still, investor confidence remains robust. The fund pulled in nearly $500 million over the past five trading sessions, pushing assets under management to roughly $8.0 billion. That flow resilience comes despite a fee gap: BlackRock’s iShares charges 0.24% annually, while Invesco has cut charges on comparable products to just 0.05%. URTH’s tracking difference of only 0.02% has helped defend its market share.

The next major calendar point is the ex-dividend date on June 15, when the fund will pay a semi-annual distribution of $1.26 per share. Before then, the market must absorb the rebalancing, fresh tariff signals and potentially another Fed communication — a three-week stretch that could test whether the current high is a launching pad or a ceiling.